Tremelimumab-induced Graves' disease

Tremelimumab

Tremelimumab (CP 675206; CP-675; CP-675,206; CP-675206; Ticilimumab) is a fully human IgG2 anitbody, which is directed against human cytotoxic T lymphocyte-associated antigen 4 (CTLA4). It is being developed by Pfizer for the treatment of various cancers. It is currently in worldwide phase III development for malignant melanoma, phase II development for colorectal cancer, gastrointestinal cance...

[Graves' disease].

Graves' Disease.

Graves’ disease was first recognized in the 19th century as a syndrome comprising an enlarged and overactive thyroid gland, an accelerated heart rate, and ocular abnormalities (Fig. 1). Critical for our current understanding of this disease was the discovery of its autoimmune basis, which results from complex interactions between genetic and environmental factors.1,2 Graves’ disease has adverse...

Graves’ Disease

Copyright © 2008 Massachusetts Medical Society. A 23-year-old woman presents with palpitations. Over the past 6 months, she has reported loose stools, a 10-lb (4.5-kg) weight loss despite a good appetite and food intake, and increased irritability. She appears to be anxious and has a pulse of 119 beats per minute and a blood pressure of 137/80 mm Hg. Her thyroid gland is diffusely and symmetric...

Anticardiolipin Antibodies and Immunoglobulin M and A in Graves’ Disease

Background: Graves’ disease is an autoimmune disease, characterized by the presence of antibodies directed to TSH receptor or nearby regions as well as antibodies to double strands DNA (dsDNA) anticardiolipin and nuclear antibodies. This study evaluated anticardiolipin and rheumatoid factor, such as IgA and IgM antibodies in patients with Graves’ disease. Patients and methods: Anticardiolipin a...